Viridian Therapeutics, Inc.\DE — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Viridian announced positive Phase 1 results for VRDN-008, a subcutaneous FcRn inhibitor licensed from Paragon Therapeutics, demonstrating 74% peak IgG reduction sustained through 8 weeks with a 15–18 day half-life (6x longer than first-gen Fc fragments), supporting every-8-week dosing via the Enable enFuse injector. The company plans to initiate a registrational trial in myasthenia gravis in mid-2027 (pending regulatory feedback) with Q4W and Q8W dosing arms, and to expand development into multiple autoimmune diseases; no serious adverse events or dose-limiting toxicities were reported.
Why this rating
Lead program shows clinically meaningful differentiation (every-8-week dosing, deep/sustained suppression, favorable safety) and clear path to registrational trial in validated indication. Early-stage binary but de-risks pipeline for $943M company; market opportunity described as multi-billion-dollar per indication.
Tradability signal
NO TRADE
No trade: positive news with only +1.1% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.60% over 4 hrs, n=396). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $28.50 ▼ 2.55% | at our read · unknown $29.25 | +10 min · unknown $29.03 ▼ 0.74% | +30 min · unknown $29.73 ▲ 1.64% | +1 hr · unknown $29.63 ▲ 1.32% | +4 hrs · unknown $30.24 ▲ 3.40% |
The stock had already moved +2.61% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.